Cipla seeking for DCGI nod for importing Moderna vaccine in India

The multinational pharmaceutical company headquartered in Mumbai, Maharashtra, Cipla has sought out the Drugs controller General of India nod for importing Moderna’s COVID-19 vaccination shots.

On Monday the company had submitted an application seeking for an approval to start importing the vaccine, further sources say that the DCGI might give the green signal to do so on Tuesday itself.


Moderna’s methods for protection against COVID-19 relies on messenger RNA to program the cells to generate immunity against the coronavirus outbreak. Analyst say that the vaccine along with Pfizer are viewed as the preferred choice among wealthy countries.

Based on the clinical trials, the data states that they were more than 90% effective at preventing the symptoms of the Corona Virus. Approximately around 120 million American citizens have been vaccinated by Moderna or Pfizer shots  till now, without experiencing any major safety issues.

According to some of the agencies, Moderna vaccine will be approved only for Citizens of age 18 and above added to that only for emergency use in India.

The Moderna COVID-19 vaccine mRNA-1273 is sold under brand name of “Spikevax” in the US, which was developed by the NIAID (National Institute of Allergy and Infectious Disease). However the assessment of the safety data of the first 100 beneficiaries of the COVID-19 vaccines shall still be needed to be submitted before rolling it out for a full scale mass immunization program.

Recently the Pfizer CEO Albert Bourla had said that the companies vaccines may soon be available in India as they are in the process right now and waiting for its approval in the final stages.